Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;67(3):320-325.
doi: 10.1016/j.alit.2018.04.011. Epub 2018 May 25.

Current status of sublingual immunotherapy for allergic rhinitis in Japan

Keisuke Masuyama  1 , Tomokazu Matsuoka  2 , Atsushi Kamijo  2
Affiliations
Free article
Review

Current status of sublingual immunotherapy for allergic rhinitis in Japan

Keisuke Masuyama et al. Allergol Int. 2018 Jul.
Free article

Abstract

Japanese cedar pollen (JCP) and house dust mite (HDM) are two major allergens that cause allergic rhinitis (AR) in Japan and the prevalence of AR is increasing. Pharmacothearpy is a commonly used treatment, but the level of patient satisfaction is very low. Allergen immunotherapy (AIT) is the only therapeutic modality that provides not only symptom relief but also quality of life improvement that leads to a high rate of satisfaction. In particular, sublingual immunotherapy (SLIT) is a safe and effective treatment for AR. Here we introduce a large-scale double-blind, placebo-controlled trial of SLIT in Japanese patients using JCP droplets or HDM tablets conducted in Japan. The immediate future of SLIT in Japan is also discussed.

Keywords: Allergen immunothearpy; Allergic rhinitis; HDM allergen; Japanese cedar pollinosis; Sublingual immunotherapy.

PubMed Disclaimer